Biopharmaceutical company HedgePath Pharmaceuticals Inc (OTCQB:HPPI) announced on Monday that it proposes to change its name to INHIBITOR Therapeutics as well as a change its the ticker symbol for common and preferred stock to 'INTI' from 'HPPI'.
Both the corporate name change and ticker symbol change are expected to be effective with the opening of trading on 20 August 2019.
Following the corporate name change, INHIBITOR will launch a new website (http://www.inhibitortx.com) to showcase INHIBITOR's vision and development strategy for SUBA-Itraconazole, a proprietary formulation of the FDA approved anti-fungal drug itraconazole designed to enable improved bioavailability compared to conventional itraconazole when used as an anti-cancer treatment, as well as novel compounds that inhibit upstream targets of the Hedgehog Pathway as treatments for cancer and non-cancerous proliferation disorders.
In addition, SUBA-Itraconazole is manufactured by Mayne Pharma under current Good Manufacturing Practice standards for INHIBITOR's use in clinical trials. An affiliate of Mayne Pharma is INHIBITOR's majority stockholder and licensor of the SUBA-Itraconazole technology.
Concurrently, INHIBITOR will conduct end of Phase 2 Meeting with FDA in the fourth quarter of 2019 as well as file IND for Phase 2b clinical trial of SUBA-Itraconazole in prostate cancer. It renews and expands exclusive worldwide option agreement with the University of Connecticut for novel compounds that inhibit upstream targets of the Hedgehog Pathway.
Headquartered in Tampa, Florida, INHIBITOR Therapeutics Inc (OTCQB:INTI) is a pharmaceutical development company that discovers, develops and plans to commercialize innovative therapeutics to inhibit the progression of cancerous and non-cancerous proliferation disorders. HedgePath is the exclusive US licensee of SUBA-Itraconazole in certain fields.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study